Rituximab dose-escalation trial in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2165-2170

  O'Brien, S M ^a   Kantarjian, H ^a   Thomas, D A ^a   Giles, F J ^a   Freireich, E J ^a   Cortes, J ^a   Lerner, S ^a   Keating, M J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER GRADING; CANCER REGRESSION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DYSPNEA; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; LYMPHOCYTE COUNT; MALAISE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035871441     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2165     Document Type: Article

References (9)

1. CD20 Workshop panel report
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
3. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
4. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia
5. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
6. Evaluation of survival data and two new rank order statistics arising to consideration
7. Non-parametric estimation from incomplete observations
8. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): A feasible and active regimen
9. Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL)